Prothrombin polymorphism A19911G, factor V HR2 haplotype A4070G, and plasminogen activator-inhibitor-1 polymorphism 4G/5G and the risk of retinal vein occlusion

References

• Zöller B, Norlund L, Leksell H, et al. High prevalence oft he FVR506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis. Thromb Res 1996;83:475–477.
   PubMed Web of Science ®Google Scholar
• Zöller B, Hillarp A, Berntorp E, et al. Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis. Annu Rev Med 1997;48:45–58.
   PubMed Web of Science ®Google Scholar
• Hillarp A, Zöller B, Svensson PJ, et al. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997;78:990–992.
   PubMed Web of Science ®Google Scholar
• Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, et al. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997;78:1430–1433.
   PubMed Web of Science ®Google Scholar
• Martinelli I, Battaglioli T, Tosetto A, et al. Prothrombin A19911G polymorphism and the risk of venous thromboembolism. J Thromb Haemost 2006;4:2582–2586.
   PubMed Web of Science ®Google Scholar
• Aleksova A, Di Nucci M, Gobbo M, et al. Factor-V HR2 haplotype and thromboembolic disease. Acta Cardiol 2015;70:707–711.
   PubMed Web of Science ®Google Scholar
• Folsom AR, Cushman M, Tsai MY, et al. A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. Blood 2002;99:2720–2725.
   PubMed Web of Science ®Google Scholar
• Bernardi F, Faioni EM, Castoldi E, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein resistance phenotype. Blood 1997;90:1552–1557.
   PubMed Web of Science ®Google Scholar
• Faioni EM, Franchi F, Bucciarelli P, et al. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q (factor V Leiden). Blood 1999; 94:3062–3066.
   PubMed Web of Science ®Google Scholar
• Gori AM, Marcucci R, Fatini C, et al. Impaired fibrinolysis in retinal vein occlusion: a role for genetic determinants of PAI-1 levels. Thromb Haemost 2004;92:54–60.
   PubMed Web of Science ®Google Scholar
• Ceelie H, Bertina RM, van Hylckama Vlieg A, et al. Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost 2001;85:1066–1070.
   PubMed Web of Science ®Google Scholar
• Gong L, Proulle V, Fang C, et al. A specific plasminogen activator inhibitor-1 antagonist derived from inactivated urokinase. J Cell Mol Med 2016;20:1851–1860.
   Google Scholar
• Greiner K, Hafner G, Dick B, et al. Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol 1999;128:69–74.
   PubMed Web of Science ®Google Scholar
• Kuhli-Hattenbach C, Scharrer I, Lüchtenberg M, et al. Coagulation disorders and the risk of retinal vein occlusion. Thromb Haemost 2010;103:299–305.
   PubMed Web of Science ®Google Scholar
• Hattenbach LO, Klais C, Scharrer I. Heparin cofactor II deficiency in central retinal vein occlusion. Acta Ophthalmol Scand 1998;76:758–759.
   PubMedGoogle Scholar
• Kuhli C, Hattenbach LO, Scharrer I, et al. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefe’s Arch Clin Exp Ophthalmol 2002;240:163–168.
   PubMed Web of Science ®Google Scholar
• Wong TY, Marino Larsen EK, Klein R, et al. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli. The Atherosclerosis Risk in Communities & Cardiovascular Health Study. Ophthalmology 2005;112:540–547.
   Google Scholar
• Koizumi H, Ferrara DC, Brué C, et al. Central retinal vein occlusion case-control-study. Am J Ophthalmol 2007;144:858–863.
   PubMed Web of Science ®Google Scholar
• Kuhli C, Scharrer I, Koch F, et al. Factor XII deficiency: a thrombophilic risk factor for retinal vein occlusion. Am J Ophthalmol 2004;137:459–464.
   PubMed Web of Science ®Google Scholar
• Marcucci R, Bertini L, Giusti B, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001;86:772–776.
   PubMed Web of Science ®Google Scholar
• Rehak M, Rehak J, Müller M, et al. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. Thromb Haemost 2008;99:925–929.
   PubMed Web of Science ®Google Scholar
• Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996;80:200–202.
   PubMed Web of Science ®Google Scholar
• Janssen MCH, den Heijer M, Cru¥sberg JRM, et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? Thromb Haemost 2005;93:1021–1026.
   PubMed Web of Science ®Google Scholar
• Laurell CB: Elektroimmuno Assay. Scand J Clin Lab Invest 1972;124:21–37.
   Web of Science ®Google Scholar
• Ehrenforth S, von Depka Prondsinki M, Aygören-Pürsün E, et al. Study of the prothrombin gene 20210 GA variant in FV:Q506 carriers in relationship to the presence or absence of juvenile venous thromboembolism. Arterioscler Thromb Vasc Biol 1999;19:276–280.
   PubMed Web of Science ®Google Scholar
• Pérez-Ceballos E, Corral J, Alberca I, et al. Prothrombin A19911G and G20210A polymorphisms’ role in thrombosis. Br J Haematol 2002;118:610–614.
   PubMed Web of Science ®Google Scholar
• Chinthammitr Y, Vos HL, Rosendaal FR, et al. The 3′ end prothrombin gene variants in patients with different thrombotic events. Lab Med 2014;45:309–314.
   PubMed Web of Science ®Google Scholar
• Djordjevic V, Pruner I, Tomic B, et al. Prothrombin A19911G polymorphism and the risk of venous thromboembolism. J Thromb Haemost 2006;4:2582–2586.
   PubMed Web of Science ®Google Scholar
• Simsek E, Yesilyurt A, Pinarli F, et al. Combined genetic mutations have remarkable effect on deep venous thrombosis and/or pulmonary embolism occurrence. Gene 2014;536:171–176.
   PubMed Web of Science ®Google Scholar
• Coulam CB, Jeyendran RS, Fishel LA, et al. Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage. Am J Reprod Immunol 2006;55:360–368.
   PubMed Web of Science ®Google Scholar
• Sarig G, Younis JS, Hoffman R, et al. Thrombophilia is common in women with idiopathic pregnancy loss and is associated with late pregnancy wastage. Fertil Steril 2002;77:342–347.
   PubMed Web of Science ®Google Scholar
• Torabi R, Zarei S, Zeraati H, et al. Combination of thrombophilic gene polymorphisms as a cause of increased the risk of recurrent pregnancy loss. J Reprod Infertil 2012;13:89–94.
   PubMedGoogle Scholar
• Salomon O, Moissiev J, Rosenberg N, et al. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vascular occlusion. Blood Coagul Fibrinolysis 1998;9:617–622.
   PubMed Web of Science ®Google Scholar
• Dulícek P, Maly J, Pecka M, et al. Venous thromboembolism in young female while on oral contraceptives: high frequency of inherited thrombophilia and analysis of thrombotic events in 400 Czech women. Clin Appl Thromb Hemost 2009;15:567–573.
   PubMed Web of Science ®Google Scholar
• Arséne S, Delahousse B, Regina S, et al. Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age. Thromb Haemost 2005;94:101–106.
   PubMed Web of Science ®Google Scholar
• Lahey JM, Tunc M, Kearnea J, et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology 2002;109:126–131.
   PubMed Web of Science ®Google Scholar
• Abu el-Asrar AM, al-Momen AK, al-Amro S, et al. Prothrombotic states associated with retinal venous occlusion in young adults. Int Ophthalmol 1996-97;20:197–204.
   Google Scholar
• Simioni P, Prandoni P, Lensing AW, et al. The risk of recurrent venous thromboembolism in patients with an Arg506→Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399–403.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Martinelli I, Mannucci RM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999;341:801–806.
   PubMed Web of Science ®Google Scholar
• Anaya DA, Nathens AB. Thrombosis and coagulation: deep vein thrombosis and pulmonary embolism prophylaxis. Surg Clin North Am 2005;85:1163–1177.
   PubMed Web of Science ®Google Scholar